

**AMENDMENT TO H.R. 467, AS REPORTED
OFFERED BY MS. BLUNT ROCHESTER OF
DELAWARE**

At the end of the bill, add the following:

1 SEC. 7. STUDY ON NALOXONE ACCESS.

2 (a) IN GENERAL.—The Comptroller General of the
3 United States shall conduct a study on actions that may
4 be taken to ensure appropriate access and affordability of
5 naloxone for individuals seeking to purchase naloxone.
6 Such study shall address what is known about—

7 (1) coverage of naloxone (in any available
8 form), including whether naloxone can be covered as
9 an over-the-counter drug under a group health plan
10 or group or individual health insurance coverage (as
11 such terms are defined in section 2791 of the Public
12 Health Service Act (42 U.S.C. 300gg–91)) or for in-
13 dividuals entitled to benefits under part A or en-
14 rolled under part B of title XVIII of the Social Se-
15 curity Act (42 U.S.C. 1395 et seq.) or receiving
16 medical assistance under a State plan under title
17 XIX of such Act (42 U.S.C. 1396 et seq.) or a waiv-
18 er of such plan;

1 (2) the out-of-pocket cost to consumers pur-
2 chasing naloxone—

3 (A) with a prescription, with and without
4 coverage under any such plan or coverage;

5 (B) over-the-counter, with and without cov-
6 erage under any such plan or coverage; and

7 (C) pursuant to a standing order; and

8 (3) other factors impacting coverage, including
9 barriers in covering naloxone as an over-the-counter
10 drug, the relative net costs of naloxone when pur-
11 chased over-the-counter without insurance coverage
12 compared to when purchased with a prescription and
13 covered under a group health plan or health insur-
14 ance coverage, and the availability of naloxone pur-
15 chased and distributed through public health enti-
16 ties.

17 (b) REPORT.—Not later than 2 years after the date
18 of the enactment of this Act, the Comptroller General of
19 the United States shall submit to Congress a report that
20 contains the findings of the study conducted under sub-
21 section (a).

